Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109


Characterization of EHop-016, novel small molecule inhibitor of Rac GTPase.

Montalvo-Ortiz BL, Castillo-Pichardo L, Hernández E, Humphries-Bickley T, De la Mota-Peynado A, Cubano LA, Vlaar CP, Dharmawardhane S.

J Biol Chem. 2012 Apr 13;287(16):13228-38. doi: 10.1074/jbc.M111.334524. Epub 2012 Mar 1.


Development of EHop-016: a small molecule inhibitor of Rac.

Dharmawardhane S, Hernandez E, Vlaar C.

Enzymes. 2013;33 Pt A:117-46. doi: 10.1016/B978-0-12-416749-0.00006-3. Epub 2013 Aug 8. Review.


Characterization of a Dual Rac/Cdc42 Inhibitor MBQ-167 in Metastatic Cancer.

Humphries-Bickley T, Castillo-Pichardo L, Hernandez-O'Farrill E, Borrero-Garcia LD, Forestier-Roman I, Gerena Y, Blanco M, Rivera-Robles MJ, Rodriguez-Medina JR, Cubano LA, Vlaar CP, Dharmawardhane S.

Mol Cancer Ther. 2017 May;16(5):805-818. doi: 10.1158/1535-7163.MCT-16-0442.


Novel inhibitors of Rac1 in metastatic breast cancer.

Hernández E, De La Mota-Peynado A, Dharmawardhane S, Vlaar CP.

P R Health Sci J. 2010 Dec;29(4):348-56.


RAC1 GTP-ase signals Wnt-beta-catenin pathway mediated integrin-directed metastasis-associated tumor cell phenotypes in triple negative breast cancers.

De P, Carlson JH, Jepperson T, Willis S, Leyland-Jones B, Dey N.

Oncotarget. 2017 Jan 10;8(2):3072-3103. doi: 10.18632/oncotarget.13618.


The Rac Inhibitor EHop-016 Inhibits Mammary Tumor Growth and Metastasis in a Nude Mouse Model.

Castillo-Pichardo L, Humphries-Bickley T, De La Parra C, Forestier-Roman I, Martinez-Ferrer M, Hernandez E, Vlaar C, Ferrer-Acosta Y, Washington AV, Cubano LA, Rodriguez-Orengo J, Dharmawardhane S.

Transl Oncol. 2014 Oct 24;7(5):546-55. doi: 10.1016/j.tranon.2014.07.004. eCollection 2014 Oct.


Rational design and characterization of a Rac GTPase-specific small molecule inhibitor.

Gao Y, Dickerson JB, Guo F, Zheng J, Zheng Y.

Proc Natl Acad Sci U S A. 2004 May 18;101(20):7618-23. Epub 2004 May 5.


Rac1 and Rac3 isoform activation is involved in the invasive and metastatic phenotype of human breast cancer cells.

Baugher PJ, Krishnamoorthy L, Price JE, Dharmawardhane SF.

Breast Cancer Res. 2005;7(6):R965-74. Epub 2005 Sep 30.


Inhibition of the Rho GTPase, Rac1, decreases estrogen receptor levels and is a novel therapeutic strategy in breast cancer.

Rosenblatt AE, Garcia MI, Lyons L, Xie Y, Maiorino C, Désiré L, Slingerland J, Burnstein KL.

Endocr Relat Cancer. 2011 Feb 23;18(2):207-19. doi: 10.1677/ERC-10-0049. Print 2011 Apr.


Rational design and applications of a Rac GTPase-specific small molecule inhibitor.

Akbar H, Cancelas J, Williams DA, Zheng J, Zheng Y.

Methods Enzymol. 2006;406:554-65.


Pak and Rac GTPases promote oncogenic KIT-induced neoplasms.

Martin H, Mali RS, Ma P, Chatterjee A, Ramdas B, Sims E, Munugalavadla V, Ghosh J, Mattingly RR, Visconte V, Tiu RV, Vlaar CP, Dharmawardhane S, Kapur R.

J Clin Invest. 2013 Oct;123(10):4449-63. doi: 10.1172/JCI67509. Epub 2013 Sep 16.


Enhanced intrinsic migration of aggressive breast cancer cells by inhibition of Rac1 GTPase.

Zuo Y, Shields SK, Chakraborty C.

Biochem Biophys Res Commun. 2006 Dec 15;351(2):361-7. Epub 2006 Oct 16.


Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis.

Morrison Joly M, Williams MM, Hicks DJ, Jones B, Sanchez V, Young CD, Sarbassov DD, Muller WJ, Brantley-Sieders D, Cook RS.

Breast Cancer Res. 2017 Jun 30;19(1):74. doi: 10.1186/s13058-017-0868-8.


Blockade of Rac1 activity induces G1 cell cycle arrest or apoptosis in breast cancer cells through downregulation of cyclin D1, survivin, and X-linked inhibitor of apoptosis protein.

Yoshida T, Zhang Y, Rivera Rosado LA, Chen J, Khan T, Moon SY, Zhang B.

Mol Cancer Ther. 2010 Jun;9(6):1657-68. doi: 10.1158/1535-7163.MCT-09-0906. Epub 2010 Jun 1.


Activation of Dbl restores migration in polyamine-depleted intestinal epithelial cells via Rho-GTPases.

Ray RM, Bavaria MN, Bhattacharya S, Johnson LR.

Am J Physiol Gastrointest Liver Physiol. 2011 Jun;300(6):G988-97. doi: 10.1152/ajpgi.00409.2010. Epub 2011 Mar 3.


Mechanisms of guanine nucleotide exchange and Rac-mediated signaling revealed by a dominant negative trio mutant.

Debreceni B, Gao Y, Guo F, Zhu K, Jia B, Zheng Y.

J Biol Chem. 2004 Jan 30;279(5):3777-86. Epub 2003 Nov 3.


Structure-function based design of small molecule inhibitors targeting Rho family GTPases.

Nassar N, Cancelas J, Zheng J, Williams DA, Zheng Y.

Curr Top Med Chem. 2006;6(11):1109-16. Review.


A Rac1/Cdc42 GTPase-specific small molecule inhibitor suppresses growth of primary human prostate cancer xenografts and prolongs survival in mice.

Zins K, Lucas T, Reichl P, Abraham D, Aharinejad S.

PLoS One. 2013 Sep 11;8(9):e74924. doi: 10.1371/journal.pone.0074924. eCollection 2013.


Inactivation of Rac1 reduces Trastuzumab resistance in PTEN deficient and insulin-like growth factor I receptor overexpressing human breast cancer SKBR3 cells.

Zhao Y, Wang Z, Jiang Y, Yang C.

Cancer Lett. 2011 Dec 26;313(1):54-63. doi: 10.1016/j.canlet.2011.08.023. Epub 2011 Sep 3.


R-Ketorolac Targets Cdc42 and Rac1 and Alters Ovarian Cancer Cell Behaviors Critical for Invasion and Metastasis.

Guo Y, Kenney SR, Muller CY, Adams S, Rutledge T, Romero E, Murray-Krezan C, Prekeris R, Sklar LA, Hudson LG, Wandinger-Ness A.

Mol Cancer Ther. 2015 Oct;14(10):2215-27. doi: 10.1158/1535-7163.MCT-15-0419. Epub 2015 Jul 23.

Supplemental Content

Support Center